BIO International Convention · Jun 2026
BIO lists Delineate as a Y Combinator–backed AI startup focused on accelerating Model-Informed Drug Development.
Agents for Accelerated Clinical Trial Design
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Delineate is a Cambridge-based biopharma software startup that uses custom LLM and computer-vision workflows to extract and structure research literature, patents, figures, and plots into analysis-ready datasets for model-informed drug development and clinical-trial design.
Primary product
AI agents and evidence-synthesis software for biopharma clinical-trial design
Founded
2024
Headquarters
Cambridge, Massachusetts, United States
Team size
11-50 employees
Industry
Software Development
Sub-industry
AI for biopharma evidence synthesis and clinical trial design
Offices
1010 Massachusetts Ave, Cambridge, MA 02138, United States
Boston, Massachusetts, United States
Business model
SaaS
enterprise software
bespoke AI services
Funding
People & investors
Work & culture
Public signals suggest a technical, research-heavy, mission-driven team focused on helping pharma customers make faster evidence-based decisions; no formal benefits or culture page was found.
Product & market
Pricing
B2B enterprise contracts with bespoke services
Differentiators
- —Extracts and analyzes biopharma literature and patents at scale, including data trapped in figures and plots
- —Uses custom LLM and computer-vision models with QC processes
- —Produces analysis-ready datasets for workflows such as NONMEM and MBMA
- —Claims 15x more processed studies than industry standard and months-to-weeks turnaround
- —Supports evidence synthesis, database curation, and model replication from the same platform
Technology
Redis
Celery
Docker
Python
Jupyter
Box
R
Julia
Customers
Two top-10 pharmaceutical companies
Biopharma teams doing meta-analyses and computational analysis workflows
Sanofi (collaboration on PK database work)
Scale & contact
Latest news
PAGE Meeting · May 2026
A conference abstract reports strong performance for Delineate across systematic literature review, data extraction, and model replication workflows.
LinkedIn · Sep 2025
The company says the grant will accelerate QSP model development and repurposing, including reconstructing models from public data and validating published models.
LinkedIn · May 2025
Founder Emily Nieves says Delineate completed its seed fundraising round and thanks lead investor Cannage Capital plus co-investors Civilization Ventures and Peak XV Partners.
Y Combinator · Feb 2025
YC describes Delineate as building AI agents for faster clinical trial design, using custom LLM and computer-vision models to extract data from biopharma papers and patents.
Jobs and careers at Delineate
0 jobs at Delineate
No open positions
Check back later for new openings